# Anticoagulant Reversal in Intracerebral Hemorrhage

Treat anticoagulant-associated intracerebral hemorrhage as a time-critical hematoma-expansion emergency: identify the agent and last dose, send agent-relevant assays without delaying treatment, administer targeted reversal promptly, and coordinate blood-pressure management, repeat imaging, and neurosurgical assessment.

**Clinical question:** How should clinicians rapidly select and administer anticoagulant reversal for patients with acute intracerebral hemorrhage?

Updated: 2026-09-15T21:15:32.481019+00:00

## What matters in practice
- Initiate anticoagulant reversal immediately in anticoagulant-associated ICH; early coagulopathy correction and blood-pressure control are central measures to limit hematoma expansion. [10][19][20][24]
- For warfarin-associated ICH, use intravenous vitamin K plus prothrombin complex concentrate; these are the cornerstones of VKA reversal. [4][12]
- For apixaban- or rivaroxaban-associated ICH requiring reversal, use andexanet alfa when selected and available; 4-factor PCC 2,000 units is an alternative when andexanet is unavailable. [3]
- For dabigatran exposure, use idarucizumab; thrombin time, dilute thrombin time, and ecarin-based assays can detect dabigatran activity when available. [1][3]
- Reverse therapeutic-dose LMWH, not routine prophylactic LMWH, with time-based protamine dosing; protamine only partially reverses LMWH. [2][3]

## Treat anticoagulant-associated ICH as a reversal emergency

Do not await specialized coagulation testing before initiating indicated reversal.

In a patient with CT-confirmed ICH and current or suspected anticoagulant exposure, immediately establish the drug, dose, time of last administration, renal status, indication for anticoagulation, and whether emergency hematoma evacuation or another invasive procedure may be needed. Up to half of patients with oral-anticoagulant-associated ICH experience early clinical deterioration related to active bleeding and hematoma enlargement; rapid reversal is intended to limit expansion and facilitate surgery when necessary. [19][20][24]

Run reversal and acute ICH management in parallel: obtain CBC, PT/INR, aPTT, creatinine, type and screen, and agent-specific testing if locally available, while activating neurology/neurocritical care and neurosurgical pathways. The 2022 AHA/ASA ICH guidance emphasizes early anticoagulant reversal and early systolic blood-pressure reduction, and AHA/ASA performance measures identify a 90-minute anticoagulation-reversal target. [10][14]

Do not use a normal conventional coagulation assay to exclude clinically meaningful direct oral anticoagulant activity. Agent-specific anti-Xa assays detect rivaroxaban or apixaban activity, whereas thrombin time, dilute thrombin time, ecarin clotting time, and ecarin chromogenic assay detect dabigatran; however, calibrated assays may be unavailable or delayed. [1]
- Document the exact anticoagulant before ordering reversal whenever feasible, but do not delay treatment of life-threatening ICH for a send-out drug level. [1][24]
- If the patient received more than one antithrombotic agent, address each pharmacologic mechanism rather than assuming one reversal product corrects all contributors to bleeding. [24]
- Reassess neurologic examination and obtain repeat neuroimaging according to the institutional ICH pathway, particularly with clinical deterioration or concern for ongoing hematoma expansion. [19][20]

*Agent-directed reversal choices in anticoagulant-associated ICH. [2][3][4][12]*

| Anticoagulant exposure | Preferred or named reversal approach | Operational decision |
| --- | --- | --- |
| Warfarin or other vitamin K antagonist | Intravenous vitamin K plus PCC. [4][12] | Treat as VKA-associated coagulopathy and correct promptly; INR is the immediately available assay guiding identification and follow-up. [12] |
| Dabigatran | Idarucizumab. [3][4] | Use dabigatran-sensitive testing when available; thrombin time, dilute thrombin time, or ecarin-based testing can detect drug activity. [1] |
| Apixaban or rivaroxaban | Andexanet alfa; if unavailable, 4-factor PCC 2,000 units. [3] | Choose andexanet dose by last factor Xa inhibitor dose and time since ingestion. [3] |
| Edoxaban or betrixaban | Off-label andexanet alfa or 4-factor PCC 2,000 units. [3] | Recognize that andexanet use for these agents is off label. [3] |
| Unfractionated heparin infusion | Protamine sulfate 1 mg per 100 units of heparin received during the prior 2-3 hours; maximum 50 mg. [2] | Repeat aPTT after reversal; give half the initial protamine dose if aPTT remains elevated. [2] |
| Therapeutic-dose enoxaparin | Protamine sulfate, time-based dosing. [2] | Give 1 mg protamine per 1 mg enoxaparin if administered within 8 hours; give 0.5 mg per 1 mg if 8-12 hours earlier. [2] |

## Reverse warfarin with PCC plus intravenous vitamin K

Use combination therapy because immediate factor replacement alone does not address persistent VKA effect.

For warfarin-associated ICH, administer intravenous vitamin K and PCC promptly. Vitamin K plus PCC is the established reversal strategy for VKA-associated ICH, whereas PCC supplies vitamin K-dependent clotting factors for rapid correction and vitamin K addresses sustained warfarin effect. [4][12]

Obtain PT/INR before treatment when this does not delay therapy, then repeat INR after reversal to identify incomplete correction or recurrent anticoagulant effect. The urgent clinical objective is correction of VKA-associated coagulopathy during the period of greatest risk for hematoma expansion rather than waiting for spontaneous INR decline. [12][19][20]

Avoid substituting unstructured plasma-only strategies when PCC is available for urgent VKA reversal. FFP has been used historically in anticoagulant-associated intracranial hemorrhage, but contemporary descriptions identify vitamin K and PCC as the reversal cornerstones. [12][24]
- Give vitamin K intravenously rather than assuming PCC alone will provide durable reversal. [12]
- Continue to reassess for neurosurgical intervention after reversal, because correcting coagulopathy may permit hematoma evacuation or other urgent procedures. [24]
- Do not use 3-factor PCC or recombinant activated factor VII as routine substitutes for the established VKA approach; their use in anticoagulant-associated intracranial hemorrhage has been described as off label in the United States. [24]

*Practical warfarin-reversal sequence. [4][12][24]*

| Step | Action | What changes next |
| --- | --- | --- |
| 1 | Confirm warfarin exposure and obtain PT/INR without delaying therapy. [12] | Establishes VKA-associated coagulopathy and provides a post-treatment comparison. [12] |
| 2 | Administer intravenous vitamin K plus PCC. [4][12] | Provides immediate factor replacement and sustained reversal. [12] |
| 3 | Repeat INR after treatment. [12] | Persistent elevation should prompt reassessment of reversal adequacy and ongoing bleeding risk. [12] |
| 4 | Coordinate neurosurgical and critical-care management. [24] | Corrected coagulopathy supports consideration of hematoma evacuation when otherwise indicated. [24] |

## Match DOAC reversal to thrombin-inhibitor versus factor Xa-inhibitor exposure

The key branch is dabigatran versus apixaban or rivaroxaban.

For dabigatran-associated ICH, use idarucizumab as the specific reversal agent. If exposure is uncertain or the timing of the last dose is unclear, a thrombin time, dilute thrombin time, or ecarin-based assay can detect dabigatran activity, but limited availability and turnaround commonly constrain their use in the emergency setting. [1][3]

For apixaban- or rivaroxaban-associated ICH requiring reversal, andexanet alfa is a specific factor Xa inhibitor reversal agent approved by the FDA in 2018. It is a modified recombinant inactive factor Xa that binds and sequesters factor Xa inhibitors. Select low- versus high-dose administration according to the patient’s anticoagulant dose and time since last ingestion. [3]

The andexanet regimen is either a 400-mg or 800-mg intravenous bolus at 30 mg/min followed by 4 mg/min or 8 mg/min, respectively, for up to 120 minutes. When andexanet alfa is unavailable, 4-factor PCC 2,000 units is a recommended alternative for apixaban or rivaroxaban reversal in the cited guidance. [3]

For edoxaban or betrixaban, the cited guidance describes off-label andexanet alfa at an 800-mg bolus followed by 8 mg/min for up to 120 minutes, or 4-factor PCC 2,000 units. Make the off-label status explicit in the treatment record and involve pharmacy early when the exposure is not apixaban or rivaroxaban. [3]
- Use calibrated anti-Xa activity assays for apixaban or rivaroxaban when available, but recognize that non-calibrated or delayed testing may not provide a timely drug-specific answer. [1]
- Do not infer the degree of apixaban or rivaroxaban effect from aPTT alone; conventional coagulation assays are not quantitative measures of DOAC exposure. [1]
- When choosing andexanet dose, verify the last known dose and ingestion time from the medication record, pharmacy fill history, family, or facility record. [3]

### Andexanet alfa versus 4-factor PCC

Andexanet alfa is the specific FDA-approved reversal agent for direct factor Xa inhibitors, whereas PCC provides nonspecific replacement of vitamin K-dependent clotting factors. When andexanet is not available, the cited guidance recommends 4-factor PCC 2,000 units for apixaban or rivaroxaban. [3]

Comparative evidence remains clinically important but not definitive for individual patients: a retrospective comparison found no difference between 4-factor PCC and andexanet alfa in successful anticoagulation reversal, all-cause mortality, or other reported outcomes. Selection should therefore incorporate agent availability, time to administration, verified anticoagulant exposure, need for surgery, and thrombosis-versus-rebleeding risk. [6]
- Do not extrapolate FDA-approved andexanet use for apixaban and rivaroxaban to edoxaban or betrixaban without recognizing off-label use. [3]
- If using PCC because andexanet is unavailable, administer the cited 2,000-unit regimen rather than deferring reversal for specialized testing. [3]

*DOAC-directed testing and reversal. [1][3]*

| Suspected agent | Useful activity assay when available | Reversal action |
| --- | --- | --- |
| Dabigatran | Thrombin time, dilute thrombin time, ecarin clotting time, or ecarin chromogenic assay. [1] | Administer idarucizumab. [3] |
| Apixaban | Agent-specific anti-Xa activity assay. [1] | Andexanet alfa: 400-mg or 800-mg bolus, then 4 mg/min or 8 mg/min for up to 120 minutes based on dose and timing; 4-factor PCC 2,000 units if andexanet unavailable. [3] |
| Rivaroxaban | Agent-specific anti-Xa activity assay. [1] | Andexanet alfa: 400-mg or 800-mg bolus, then 4 mg/min or 8 mg/min for up to 120 minutes based on dose and timing; 4-factor PCC 2,000 units if andexanet unavailable. [3] |
| Edoxaban or betrixaban | Agent-specific anti-Xa activity assay if available. [1] | Off-label andexanet alfa 800-mg bolus then 8 mg/min for up to 120 minutes, or 4-factor PCC 2,000 units. [3] |

## Use protamine according to heparin formulation and time since dosing

Separate continuous unfractionated heparin exposure from therapeutic-dose LMWH.

For ICH during an unfractionated heparin infusion, stop the infusion and administer intravenous protamine sulfate at 1 mg per 100 units of heparin received during the preceding 2-3 hours, to a maximum of 50 mg. Repeat aPTT after treatment; if aPTT remains elevated, repeat protamine at one-half of the initial dose. [2]

For subcutaneous prophylactic unfractionated heparin, do not routinely reverse solely because ICH is present. Consider protamine only when aPTT is significantly prolonged in the setting of new hemorrhage, because therapeutic rather than prophylactic anticoagulant effect is the actionable target. [2]

For therapeutic-dose enoxaparin, give protamine 1 mg per 1 mg enoxaparin when the last dose was within 8 hours, or 0.5 mg per 1 mg when it was 8-12 hours earlier. For dalteparin, nadroparin, or tinzaparin, use 1 mg protamine per 100 anti-Xa units, with a maximum dose of 50 mg. [2]

LMWH reversal with protamine is partial. If bleeding continues or renal insufficiency raises concern for persistent LMWH effect, the cited regimen permits a repeat dose equal to one-half the initial protamine dose; recombinant factor VIIa is generally not recommended and is considered only if protamine is contraindicated. [2][3]
- Time the protamine dose from actual medication administration, not the scheduled administration time. [2]
- Use repeat aPTT to assess residual unfractionated heparin effect after protamine; aPTT is not a quantitative monitor for DOAC activity. [1][2]
- For LMWH exposure, identify the exact product because dosing is expressed as mg for enoxaparin but anti-Xa units for dalteparin, nadroparin, and tinzaparin. [2]

*Protamine regimens for anticoagulant-associated ICH. [2]*

| Exposure | Initial protamine regimen | Reassessment or repeat-dose rule |
| --- | --- | --- |
| Unfractionated heparin infusion | 1 mg per 100 units administered in the prior 2-3 hours; maximum 50 mg. [2] | Repeat aPTT; if elevated, give one-half the initial protamine dose. [2] |
| Prophylactic subcutaneous unfractionated heparin | Consider reversal only with significantly prolonged aPTT in new hemorrhage. [2] | Avoid routine reversal when there is no evidence of clinically meaningful heparin effect. [2] |
| Enoxaparin within 8 hours | 1 mg per 1 mg enoxaparin. [2] | For continued bleeding or renal insufficiency, repeat one-half of the initial dose. [2] |
| Enoxaparin 8-12 hours earlier | 0.5 mg per 1 mg enoxaparin. [2] | For continued bleeding or renal insufficiency, repeat one-half of the initial dose. [2] |
| Dalteparin, nadroparin, or tinzaparin | 1 mg per 100 anti-Xa units; maximum 50 mg. [2] | For continued bleeding or renal insufficiency, repeat one-half of the initial dose. [2] |

## Monitor for hematoma progression, procedural needs, and the anticoagulation restart decision

Reversal is only one component of the acute ICH pathway.

After reversal, monitor neurologic status, blood pressure, and imaging for evidence of hematoma enlargement. Hematoma expansion and early neurologic decline remain central threats in oral-anticoagulant-associated ICH; rapid coagulopathy correction and blood-pressure control are the principal acute medical measures directed at these risks. [19][20]

Escalate early to neurosurgery when the clinical or radiographic course raises concern for hematoma evacuation or another urgent intracranial procedure. Anticoagulant correction is particularly important when surgery is being considered because it may facilitate operative intervention and reduce continued bleeding risk. [24]

Do not set a routine anticoagulation-restart date at the time of emergency reversal. Restart should be individualized after hematoma stability, hemorrhage mechanism, thromboembolic indication, and rebleeding risk have been reassessed. A cited consensus framework supports resuming anticoagulation once thrombotic risk exceeds rebleeding risk; in some non-neurovascular major-bleeding scenarios this can occur within 1 week, but neurointerventional data are less clear. [3]
- Record the reversal agent, dose, administration time, anticoagulant indication, and last known anticoagulant dose to support subsequent thrombosis-risk decisions. [3][24]
- Reassess renal function in DOAC and LMWH exposure because impaired clearance can prolong clinically relevant anticoagulant activity and may influence repeat-dose considerations for LMWH reversal. [2]
- Avoid a false sense of security after reversal: continued neurologic decline should trigger urgent reassessment for hematoma expansion, hydrocephalus, or a procedural complication requiring neurosurgical action. [19][20][24]

*Post-reversal decisions that change management. [2][3][19][20][24]*

| Finding | Immediate interpretation | Next action |
| --- | --- | --- |
| New neurologic decline after reversal | Possible hematoma enlargement or another ICH complication. [19][20] | Urgently reassess clinically and obtain repeat neuroimaging through the acute ICH pathway. [19][20] |
| Persistently elevated aPTT after protamine for unfractionated heparin | Residual heparin effect may remain. [2] | Give one-half the initial protamine dose as specified. [2] |
| Continued bleeding after LMWH reversal or renal insufficiency | Protamine provides partial LMWH reversal and persistent effect may occur. [2][3] | Consider one-half the initial protamine dose. [2] |
| Need for urgent neurosurgical procedure | Coagulopathy may complicate operative management. [24] | Coordinate reversal completion and neurosurgical decision-making without delay. [24] |
| Considering anticoagulant resumption | Balance the original thrombotic indication against recurrent bleeding risk. [3] | Individualize timing after hematoma stability and multidisciplinary review; neurovascular-specific timing remains less certain. [3] |

## Common questions

### Should reversal wait for an anti-Xa level in a patient with suspected apixaban-associated ICH?

No. Agent-specific anti-Xa testing can identify apixaban or rivaroxaban activity, but calibrated assays may be unavailable or delayed. In life-threatening ICH, proceed with agent-directed reversal based on a credible exposure history while testing is obtained when feasible. [1][3][24]

### When is protamine indicated for low-molecular-weight heparin-associated ICH?

Use protamine for therapeutic-dose LMWH rather than routine prophylactic LMWH. For enoxaparin, dose by time since administration; recognize that reversal is partial and that continued bleeding or renal insufficiency may justify a half-dose repeat. [2][3]

## References
1. Laboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT | Trauma Surgery & Acute Care Open — tsaco.bmj.com — https://tsaco.bmj.com/content/3/1/e000231
2. Current management of spontaneous intracerebral haemorrhage | Stroke and Vascular Neurology — svn.bmj.com — https://svn.bmj.com/content/2/1/21
3. Antiplatelets and antithrombotics in neurointerventional procedures — jnis.bmj.com — https://jnis.bmj.com/content/neurintsurg/early/2023/05/15/jnis-2022-019844.full.pdf
4. Anticoagulation associated intracerebral haemorrhage trends ... — neurologyopen.bmj.com — https://neurologyopen.bmj.com/content/8/1/e001239.full.pdf
5. Coagulopathy reversal in intracerebral haemorrhage — svn.bmj.com — https://svn.bmj.com/content/5/1/29
6. Evaluation of Direct Oral Anticoagulant Reversal Agents in ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798156
7. Prothrombin Complex Concentrate vs Conservative ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2814570
8. Oral anticoagulant reversal and mortality in trauma patients — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00510-3/fulltext
9. 2024 AHA/ASA Performance and Quality Measures for Spontaneous ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STR.0000000000000464
10. Time to Acute Treatment in Intracerebral Hemorrhage Lags ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STROKEAHA.125.051422
11. Evidence for Andexanet Alpha in Reversing Intracerebral ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.031825
12. Anticoagulant-Associated Intracranial Hemorrhage in the ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/strokeaha.116.013343
13. Clinical guideline highlights for the hospitalist: 2022 American ... — shmpublications.onlinelibrary.wiley.com — https://shmpublications.onlinelibrary.wiley.com/doi/10.1002/jhm.13051
14. Consensus Recommendations for Clinical Pharmacist Integration ... — accpjournals.onlinelibrary.wiley.com — https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/jac5.70246
15. Reversal strategies for non-vitamin K antagonist oral anticoagulants — academic.oup.com — https://academic.oup.com/eurheartj/article-pdf/38/22/1710/70580011/eurheartj_38_22_1710.pdf
16. Anticoagulation reversal in the era of the non-vitamin K oral ... — academic.oup.com — https://academic.oup.com/europace/article/18/7/955/2467027
17. Updated European Heart Rhythm Association Practical Guide on the ... — academic.oup.com — https://academic.oup.com/europace/article/17/10/1467/2467018
18. the use of non-vitamin K dependent new oral anticoagulant(s) in ... — academic.oup.com — https://academic.oup.com/eurheartjsupp/article/19/suppl_D/D293/3792739
19. Anticoagulant-associated intracerebral hemorrhage — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589238X20300073
20. Anticoagulant-associated intracerebral hemorrhage - ScienceDirect — www.sciencedirect.com — http://www.sciencedirect.com/science/article/pii/S2589238X20300073
21. Intracerebral Hemorrhage — journals.lww.com — https://journals.lww.com/continuum/fulltext/2021/10000/intracerebral_hemorrhage.6.aspx
22. Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0025619611609701
23. Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0736467913014236
24. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/25081496

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.